NJ-OPENGEAR
15.2.2024 14:01:31 CET | Business Wire | Press release
Opengear, a Digi International Inc. company (NASDAQ, DGII, www.digi.com) and provider of secure and Smart Out of Band management solutions, today launched Smart Management Fabric, extending the value and functionality of Opengear’s Network Resilience platform with dynamic routing-based IP access.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240215435727/en/
Opengear Enhances Remote Access with Smart Management Fabric (SMF) and Dynamic Routing-based IP Access (Photo: Business Wire)
Lighthouse Automation Edition (AE) and Opengear's appliance software have been upgraded to include dynamic routing, allowing for a complete management network overlay. These updates enable users or machines, through automation or configuration tools, to connect to the resources they need to access or manage. They support a range of commonly used technologies such as the secure shell (SSH), hypertext transfer protocol (HTTP), graphic user interface (GUI), service processors (SPs), baseboard management controller (BMC), remote desktop protocol (RDP), network automation tools, and server management software for virtualized environments.
The new SMF is the outcome of countless hours of interaction and engagement with customers, alliances and collaborators. These exchanges have enabled Opengear to gain insight into how the latest market dynamics and technological advancements impact IT network and infrastructure management. These insights will drive the company's strategic direction for the next several years, starting with Smart Management Fabric.
SMF forms a unified management framework and makes Opengear’s network resilience platform valuable for the whole IT organization, from network engineers and system admins to support staff who need access to IP-based resources. These teams can now quickly provision and access their server-management tools as well as manage any IP-based physical or virtual resources. Additionally, network engineers can use their favorite automation tools to provision, monitor, and manage their IP endpoints at scale.
“At Opengear, we are committed to providing world-class solutions for secure and resilient access to connect, configure, or restore connected IT resources,” said Opengear President Gary Marks. “Opengear has once again redefined out of band management with SMF and routed IP-access. SMF allows customers to leverage the Opengear solution to deliver the best possible day 0/1 experience, becoming the basis to deploy, manage, and remediate connected network resources from anywhere.”
For more information, please reach out to Opengear’s sales team for a live demo and visit: https://opengear.com/products/lighthouse/.
About Opengear
Opengear, a Digi International company, delivers secure, resilient access and automation to support critical IT infrastructure on the First Day, Worst Day and Every Day. Through presence and proximity, Opengear solutions enable provisioning, orchestration, and remote management of network devices through innovative software and appliances. Opengear solutions are trusted by global organizations across financial, digital communications, retail, and manufacturing sectors. The company is headquartered in New Jersey, with an R&D center in Brisbane, Australia. For more information, visit www.opengear.com/.
About Digi International
Digi International (NASDAQ: DGII) is a leading global provider of business and mission-critical Internet of Things (IoT) connectivity products and solutions. We help our customers create next-generation connected products and solutions to deploy, monitor, and manage critical communications infrastructures and compliance standards in demanding environments with high levels of security, relentless reliability, and bulletproof performance. Founded in 1985, the company has helped customers connect more than 100 million things – and counting. For more information, visit www.digi.com, or call 877-912-3444 (U.S.) or 952-912-3444 (International).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240215435727/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom